Donate to Research


Liz Darlison, MBE

Liz has been a consultant nurse at the university hospitals of Leicester since 2004 focusing exclusively on mesothelioma. Liz is the founder and CEO of Mesothelioma UK the national charity for Mesothelioma.

Dr. Nada Nusrat

Medical doctor and postdoctoral researcher in molecular medicine and cancer therapy. My primary focus of work at the University of Leicester is targeting the CDKN2A and MTAP genes in mesothelioma-related 9p21 deletion.

Jake Spicer

I completed my undergraduate degree in biochemistry at the University of Leicester in 2018. Following this I completed a molecular pathology and therapeutics of cancer master degree in 2019 at the University of Leicester. I then took a year out before returning to Leicester in 2020 to undertake a PhD with Professor Dean Fennell, focusing on targeting homologous recombination deficiencies in mesothelioma

Molly Scotland

Research Nurse – Hope Trials Facility, Leicester Royal Infirmary from 2017 to present. Chemotherapy Nurse – Chemotherapy Suite, Leicester Royal Infirmary 2013- 2017 Staff Nurse – Renal Transplant Unit, Leicester General Hospital 2013

Dr. Charlotte Poile

Charlotte joined the Mesothelioma Research Group in 2018. Charlotte plays an essential role in ensuring regulatory (REC, HTA, GCP) compliance within the research programme. Her work also involves contributing to the development and execution of national translational research projects and clinical trials and she also works closely with international commercial partners. Charlotte has a key role in coordinating the translational research studies within different Universities and NHS departments. Her work also involves overseeing the sequencing stage of the translational projects.

Dr. Aleksandra Bzura

Aleksandra, a former PhD student of Prof Fennell, is a dedicated researcher in molecular and cellular biology. Her work focuses on the advancement of cancer therapeutics through the meticulous in vitro and ex vivo investigation of complex mechanisms in response to DNA damage therapies. Aleksandra is skilled in conducting and optimization of translational research, including the establishment of patient-derived primary cell lines.

back to top